Drug Type CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Phase 1 | Taiwan Province | 01 May 2025 | |
Diffuse large B-cell lymphoma recurrent | Phase 1 | Taiwan Province | 01 May 2025 | |
Diffuse large B-cell lymphoma refractory | Phase 1 | Taiwan Province | 01 May 2025 | |
Follicular Lymphoma | Phase 1 | Taiwan Province | 01 May 2025 | |
High grade B-cell lymphoma | Phase 1 | Taiwan Province | 01 May 2025 | |
Primary mediastinal large B-cell lymphoma recurrent | Phase 1 | Taiwan Province | 01 May 2025 | |
Primary mediastinal large B-cell lymphoma refractory | Phase 1 | Taiwan Province | 01 May 2025 | |
B-Cell Leukemia | Preclinical | China | 16 Apr 2023 |